Elevation of the serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia

被引:69
作者
Hasegawa, D
Kojima, S
Tatsumi, E
Hayakawa, A
Kosaka, Y
Nakamura, H
Sako, M
Osugi, Y
Nagata, S
Sano, K
机构
[1] Kobe Univ, Sch Med, Dept Pediat, Chuo Ku, Kobe, Hyogo 650, Japan
[2] Kobe Univ, Sch Med, Dept Tumor Genet, Chuo Ku, Kobe, Hyogo 650, Japan
[3] Nagoya First Hosp, Japanese Red Cross, Childrens Med Ctr, Div Hematol & Oncol, Nagoya, Aichi, Japan
[4] Osaka City Gen Hosp, Dept Pediat, Osaka, Japan
[5] Osaka Univ Hosp, Dept Pediat, Osaka 553, Japan
[6] Osaka Univ, Sch Med, Dept Genet, Osaka, Japan
关键词
D O I
10.1182/blood.V91.8.2793.2793_2793_2799
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fas ligand (Fast) is a membrane protein that is expressed in activated T cells and natural killer cells. Fast binds to Fas on target cells and induces apoptosis. There exists a soluble form of Fast (sFasL), and sFasL also induces apoptosis of Fas-bearing cells. The serum sFasL concentrations were reported to be elevated in patients with large granular lymphocytic leukemia and natural killer cell lymphoma. In this study, we have measured serum sFasL concentrations in other hematological disorders, including severe aplastic anemia (SAA), hemophagocytic lymphohistiocytosis (HLH), and Diamond-Blackfan anemia (DBA). The serum sFasL concentration of age-matched healthy controls was 0.16 +/- 0.11 ng/mL (mean +/- SD, n = 22). The serum sFasL levels in the patients with HLH and DBA were 3.75 +/- 3.82 (n = 19; P < .0001, HLH v control) and 2.76 +/- 2.43 ng/mL (n = 6; P = .012, DBA v control), respectively. Serum interferon-gamma concentration was elevated in the patients with HLH (1.61 +/- 2.62 ng/mL) but not in those with DBA (below the detectable level). These results suggest that the Fas-FasL system plays a role, at least in part, in the pathophysiology of HLH and DBA, (C) 1998 by The American Society of Hematology.
引用
收藏
页码:2793 / 2799
页数:7
相关论文
共 44 条
  • [1] ABSENCE OF ABNORMALITIES OF C-KIT OR ITS LIGAND IN 2 PATIENTS WITH DIAMOND-BLACKFAN ANEMIA
    ABKOWITZ, JL
    BROUDY, VC
    BENNETT, LG
    ZSEBO, KM
    MARTIN, FH
    [J]. BLOOD, 1992, 79 (01) : 25 - 28
  • [2] Arico M, 1996, LEUKEMIA, V10, P197
  • [3] Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes
    Bouscary, D
    DeVos, J
    Guesnu, M
    Jondeau, K
    Viguier, F
    Melle, J
    Picard, F
    Dreyfus, F
    FontenayRoupie, M
    [J]. LEUKEMIA, 1997, 11 (06) : 839 - 845
  • [4] Hepatitis-associated aplastic anemia
    Brown, KE
    Tisdale, J
    Barrett, AJ
    Dunbar, CE
    Young, NS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) : 1059 - 1064
  • [5] BROXMEYER HE, 1983, J IMMUNOL, V131, P1300
  • [6] Mutations in the erythropoietin receptor gene are not a common cause of Diamond-Blackfan anemia
    Dianzani, I
    Garelli, E
    Dompe, C
    Crescenzio, N
    Locatelli, F
    Schiliro, G
    Castaman, G
    Bagnara, GP
    Olivieri, NF
    Gabutti, V
    Ramenghi, U
    [J]. BLOOD, 1996, 87 (06) : 2568 - 2572
  • [7] DRACHTMAN RA, 1992, BLOOD, V79, P2177
  • [8] DOMINANT INTERFERING FAS GENE-MUTATIONS IMPAIR APOPTOSIS IN A HUMAN AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME
    FISHER, GH
    ROSENBERG, FJ
    STRAUS, SE
    DALE, JK
    MIDDELTON, LA
    LIN, AY
    STROBER, W
    LENARDO, MJ
    PUCK, JM
    [J]. CELL, 1995, 81 (06) : 935 - 946
  • [9] INVOLVEMENT OF THE CD95 (APO-1/FAS) RECEPTOR AND LIGAND IN LIVER-DAMAGE
    GALLE, PR
    HOFMANN, WJ
    WALCZAK, H
    SCHALLER, H
    OTTO, G
    STREMMEL, W
    KRAMMER, PH
    RUNKELL, L
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (05) : 1223 - 1230
  • [10] Potential involvement of fas and its ligand in the pathogenesis of Hashimoto's thyroiditis
    Giordano, C
    Stassi, G
    DeMaria, R
    Todaro, M
    Richiusa, P
    Papoff, G
    Ruberti, G
    Bagnasco, M
    Testi, R
    Galluzzo, A
    [J]. SCIENCE, 1997, 275 (5302) : 960 - 963